Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
Autor: | A. Dal Pra, K Chadwick, Eva Christensen, Pieter H. Anborgh, Charles Catton, Robert G. Bristow, Cynthia Ménard, Neil Fleshner, Ann F. Chambers, Melania Pintilie, Michael Milosevic, John Thoms |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2012 |
Předmět: |
Oncology
Male Cancer Research Pathology medicine.medical_specialty osteopontin medicine.medical_treatment urologic and male genital diseases chemotherapy Metastasis surgery Prostate cancer stomatognathic system Risk Factors Internal medicine medicine Biomarkers Tumor Humans Osteopontin External beam radiotherapy Prospective Studies Neoplasm Metastasis Molecular Diagnostics radiotherapy Aged Taxane biology business.industry Prostatectomy biomarkers Prostatic Neoplasms Middle Aged medicine.disease prostate cancer Prognosis Radiation therapy biology.protein Disease Progression Biomarker (medicine) Neoplasm Recurrence Local business |
Zdroj: | British Journal of Cancer |
ISSN: | 1532-1827 0007-0920 |
Popis: | Background: High plasma osteopontin (OPN) has been linked to tumour hypoxia, metastasis, and poor prognosis. This study aims to assess whether plasma osteopontin was a biomarker of increasing progression within prostate cancer (PCa) prognostic groups and whether it reflected treatment response to local and systemic therapies. Methods: Baseline OPN was determined in men with localised (n=199), locally recurrent (n=9) and castrate-resistant, metastatic PCa (CRPC-MET; n=37). Receiver-operating curves (ROC) were generated to describe the accuracy of OPN for distinguishing between localised risk groups or localised vs metastatic disease. We also measured OPN pre- and posttreatment, following radical prostatectomy, external beam radiotherapy (EBRT), androgen deprivation (AD) or taxane-based chemotherapy. Results: The CRPC-MET patients had increased baseline values (mean 219; 56–513 ng ml−1; P |
Databáze: | OpenAIRE |
Externí odkaz: |